International Growth Fund | Lord Abbett Mutual Funds

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

 

International Growth Fund

Track this Fund
Add to Hypo Tool

Summary

Summary

What is the International Growth Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of international companies.

Fund Basicsas of 11/29/2024

Total Net Assets
$2.89 M
Inception Date
06/28/2021
Dividend Frequency
Annually
Fund Gross Expense Ratio
9.37%
Fund Net Expense Ratio
0.95%
Number of Holdings
88
Minimum Initial Investment
$1,500+

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 06/24/2021
w/o sales charge 12.35% 18.02% -0.82% - - -1.52%
Lipper Category Avg. International Large-Cp Gro Fds 8.91% 14.44% 0.13% - - -
MSCI AC WORLD INDX ex USA GROWTH Net USD 7.37% 12.50% -1.00% - - -2.16%
w/ sales charge 5.90% 11.21% -2.76% - - -3.20%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 06/24/2021
w/o sales charge 17.10% 31.04% 1.00% - - -0.35%
Lipper Category Avg. International Large-Cp Gro Fds 13.54% 26.50% 1.36% - - -
MSCI AC WORLD INDX ex USA GROWTH Net USD 14.06% 26.75% 0.81% - - -0.44%
w/ sales charge 10.37% 23.53% -0.98% - - -2.13%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

INVESTMENT TEAM

Matthias A. Knerr
Matthias A. Knerr, CFA

Portfolio Manager

29 Years of Industry Experience

Sue Kim
Sue Kim

Partner, Director of Global and Emerging Market Equities

24 Years of Industry Experience

Supported By 35 Investment Professionals with 20 Years Avg. Industry Experience

YOUR REPRESENTATIVE

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 06/24/2021
w/o sales charge 12.35% 18.02% -0.82% - - -1.52%
Lipper Category Avg. International Large-Cp Gro Fds 8.91% 14.44% 0.13% - - -
MSCI AC WORLD INDX ex USA GROWTH Net USD 7.37% 12.50% -1.00% - - -2.16%
w/ sales charge 5.90% 11.21% -2.76% - - -3.20%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 06/24/2021
w/o sales charge 17.10% 31.04% 1.00% - - -0.35%
Lipper Category Avg. International Large-Cp Gro Fds 13.54% 26.50% 1.36% - - -
MSCI AC WORLD INDX ex USA GROWTH Net USD 14.06% 26.75% 0.81% - - -0.44%
w/ sales charge 10.37% 23.53% -0.98% - - -2.13%

Fund Expense Ratio :

Gross 9.37%

Net 0.95%

Year Fund Returns MSCI AC WORLD INDX ex USA GROWTH Net USD
2023 15.47% 14.03%
2022 -26.83% -23.05%
Year Q1 Q2 Q3 Q4
2024 10.61% 1.79% 4.01% -
2023 10.74% 2.88% -9.42% 11.90%
2022 -14.42% -14.91% -9.72% 11.30%

NAV Historical Prices

Date Net Asset Value

Portfolio

Portfolio

Region Weighting Fund Change from Previous Quarter
Europe ex-U.K. arrowDown1.9%
Asia/Pacific arrowUp0.8%
Americas arrowUp0.4%
Japan arrowDown0.9%
United Kingdom 0.0%
Cash arrowUp1.4%
Others arrowUp0.2%

Portfolio Positioningas of 09/30/2020

  • The Fund continues to have a large overweight in the information technology and industrials sectors. The portfolio is positioned to benefit from the launch of 5G wireless devices and services, continued digital business transformation, the growth in e-commerce, and investments in factory automation.
  • We decreased the Fund’s allocation to the financials sector taking profits following its recent bounce back. Within the sector, we continue to favor insurance and high quality banking franchises with strong capital positions as we believe the COVID effects on economic growth and bank loan losses remain extremely uncertain.
  • Although we need to be wary of a potential second wave of COVID-19 infections, we expect that we will see continued slow, but steady progress in economic recovery and as we do, individuals and companies will adapt and adjust to this new operating environment. Most importantly, as we look forward to 2021, we are optimistic that we will have put the necessary processes in place and developed innovative medical solutions that will enable us to move forward once again.
  • Additional key risks include the 2020 U.S. Presidential election, ongoing U.S.-China relations, and a potential second wave of COVID.

Portfolio Details as of 11/29/2024

Total Net Assets
$2.89 M
Number of Holdings
88
Weighted Average Market Cap.
221.0 B
P/B Ratio
5.3x
P/E Ratio
30.5x

Dividends & Cap Gains

Dividends & Cap Gains

Dividend Payments

Dividend Payments

For
YTD Dividends Paidas of 12/11/2024
$0
Dividend Frequency
Annually
Record Date Ex-Dividend Date Reinvest & Payable Date Dividend Reinvest Price
12/18/2023 12/19/2023 12/19/2023 $0.05930 $12.51

Upcoming Dividend Payment Dates

This section lists all anticipated income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date Reinvest & Payable Date
12/16/2024 12/17/2024 12/17/2024

Fees & Expenses

Fees & Expenses

Sales Charge Schedule as of 12/11/2024

  Sales Charge Dealer's Concession Prices at Breakpoint
Less than $100,000,000 0.00% 0.00% $15.29

Expense Ratioas of 11/30/2024

Fund Gross Expense Ratio 9.37%
Fund Net Expense Ratio 0.95%

Fund Documents

Fund Documents

0Documents selected
Portfolio Holdings 1Q
Publish Date:11/03/2015
Portfolio Holdings 3Q
Publish Date:11/03/2015
Summary Prospectus
Publish Date:11/03/2015
Statutory Prospectus
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Tailored Shareholder Report
Publish Date:11/03/2015
* includes items 7-11 of form N-CSR as required, if any.

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field